non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
National Hospital Organization Hokkaido Cancer Center
Thoracic Oncology Research Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed diagnosis of non-small cell lung cancer. 2. Unresectable and not amenable to definitive radiotherapy Stage III disease, Stage IV disease, or postoperative recurrence. 3. Age >= 20 years at the time when the results of insurance-covered multiplex genetic testing became available. 4. Patients must have undergone one of the specified multiplex gene tests under insurance coverage before the initiation of first-line therapy for advanced or recurrent disease between January 1, 2021 and December 31, 2024. Patients receiving best supportive care or those who have not yet started treatment at the time of enrollment are also eligible. - Oncomine Dx Target Test Multi-CDx System (ODxTT) - AmoyDx Lung Cancer Multi-Gene PCR Panel (Amoy) - Lung Cancer Compact Panel Dx Multi-Companion Diagnostic System (CP) 5. Patient information can be collected from medical records.
Exclusion criteria
Exclusion criteria: Patients who refused to participate in this study by opting out
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall positivity rate of gene mutations/translocations identified by multiplex genetic | — |
Secondary
| Measure | Time frame |
|---|---|
| Positivity rate of gene mutations/translocations for each multiplex assay Proportion of patients receiving molecular targeted therapy and corresponding treatment efficacy (ORR, TTD, PFS, OS) for each gene mutation/translocation Treatment efficacy of non-targeted therapies for each gene mutation/translocation (ORR, TTD, PFS, OS) Proportion of cases with newly identified gene mutations/translocations among patients who underwent CGP testing | — |
Countries
Japan
Contacts
Public ContactMotoki Sekikawa
Teine Keijinkai Hospital Respiratory Medicine
Outcome results
None listed